Liquid biopsy for detection of somatic mutations in circulating cell-free tumor DNA (ctDNA) from a blood sample
WHY LIQUID BIOPSY?
“Liquid biopsy” is a safe, non-invasive, highly sensitive and cost effective method of analyzing circulating tumor DNA (ctDNA) from the plasma of patients diagnosed with cancer or from individuals who may have cancer.
By analyzing ctDNA isolated from a patient’s blood, we can identify clinically relevant genomic alterations in ctDNA and match these alterations to targeted therapies and clinical trials.
OnkoGENETIKSTM Liquid Biopsy gene panel covers a broad spectrum of high priority genes which are known to be most involved in cancer progression. The genes are stated as the following: (Hotspot regions are being analyzed for certain genes)
For more information download the PDF brochure